Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDennis KimFMFrancesco MannelliJGJosep F Nomdedeu Guinot

Discussion

Loading...

Member takes

Overview

Analysis finds survival outcomes in Acute Myeloid Leukemia with targeted therapy and MRD assessment, suggesting new benchmarks for treatment.

Key Points

  • Median overall survival in intensively treated patients ranged from 16 months to not reached, depending on risk category.
  • Data from 1457 patients across 14 centers were analyzed using multiparameter flow cytometry and next-generation sequencing for MRD evaluation.
  • Observational analysis utilized real-world data from European LeukemiaNet participating centers to assess treatment strategies and outcomes.
  • This highlights the need for standardized MRD practices in both intensive and non-intensive treatments.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da03https://doi.org/10.1182/blood-2025-5183
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes following MRD relapse in AML patients monitored by droplet digital PCR2025
  2. 2Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  3. 3A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  4. 4A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study2025 · 1 citations
  5. 5Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients2025